Previous 10 | Next 10 |
Accelerate Diagnostics (NASDAQ:ARDX) is trading 7.2% higher after the company announced on Monday the commercialization of its new Accelerate Arc Module and BC (blood culture) kit for accurate microbial identification for positive blood cultures. The company said the Accel...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Cantor Fitzgerald analyst Louise Chen downgraded Ardelyx (ARDX -6.4%) to Neutral from Overweight with a $1 price target, down from $7. Chen sees increasing execution and competitive risks for the launches of Tenapanor in both Irritable Bowel Syndrome With Constipation and hyperphosphatemia. S...
Ardelyx, Inc. (ARDX) Q1 2022 Earnings Conference Call May 05, 2022, 16:30 PM ET Company Participants Justin Renz - Chief Financial Officer Mike Raab - President and Chief Executive Officer Susan Rodriguez - Chief Commercial Officer Robert Blanks - Chief Regulatory Affairs and Quality Assuranc...
Ardelyx press release (NASDAQ:ARDX): Q1 GAAP EPS of -$0.21 in-line. Revenue of $0.47M (-92.9% Y/Y) misses by $0.41M. As of Mar. 31, 2022, the company had total cash, cash equivalents and investments of $89.7M, as compared to total cash, cash equivalents and investments of $116.7M as of Dec. 3...
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights PR Newswire Conference Call Scheduled for 4:30 PM Eastern Time Today WALTHAM, Mass. , May 5, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceut...
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of...
Positive interim response for appeal of XPHOZAH received for CKD-PH patients; Advisory Committee could possibly turn things around for possible FDA approval. IBSRELA launched commercially in the United States on April 4, 2022; IBS-C market proven with revenues generated by sales of Li...
Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022 PR Newswire — Conference Call scheduled for 4:30 PM Eastern Time WALTHAM, Mass. , April 28, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutica...
What to Know About Buying Penny Stocks on April 25th With another day of trading penny stocks here, there is a lot for investors to consider. Now, with so much going on in the stock market in the past few months, investors should be used to a high level of volatility. [Read More] ...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, de...
WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, ...
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-q...